Á¦30ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (1ÀÏÂ÷)-¿Â/¿ÀÇÁ º´Çà : 2023-06-29
±³À°ÀÏÀÚ : 2023-06-29
±³À°Àå¼Ò : ¿¬¼¼´ëÇб³ ¹Ì·¡Ä·ÆÛ½º ÄÁ¹öÀü½º Ȧ ¹× Çмú´ëȸ ȨÆäÀÌÁö
±³À°ÁÖÁ¦ : Á¦30ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (1ÀÏÂ÷)-¿Â/¿ÀÇÁ º´Çà
ÁÖÃÖ±â°ü : ´ëÇѱâÃÊÀÇÇÐÇùÀÇȸ
´ã´çÀÚ : ÇѼö¾Æ
¿¬¶ôó : 053-766-0006
À̸ÞÀÏ : kbms@gbc.or.kr
±³À°Á¾·ù : ÀÇ»çÇÐ, ¹ýÀÇÇÐ, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ±â»ýÃæÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀÎ : 1000¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : °¿øµµ
±³À°½Ã°£ : 23 ½Ã°£ 5ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í ±³¼ö, ÀÇ»ç, ¼±ÀÓ¿¬±¸¿ø, ¿¬±¸±â°ü °ø¹«¿ø (100,000¿ø) / ´ëÇпø»ý, Àü°øÀÇ, ±ºÀÇ°ü, ¿¬±¸¿ø, °£È£»ç, ±âŸ (50,000¿ø) / Çкλý, ÀÇ°ú´ëÇлý, ±âÃʱ³½Ç¸í¿¹±³¼ö (¹«·á)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 10:00~10:30 ±¹³» ÀÇ·á±â±â »ê¾÷ÀÇ ÇöÀç¿Í ¹Ì·¡ ¾ç¸í¹è(¿øÁÖÀÇ·á±â±âÅ×Å©³ë¹ë¸®)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 10:30~11:00 µðÁöÅÐÇコÄÉ¾î °¿ø±ÔÁ¦ÀÚÀ¯Æ¯±¸ À±¿ÏÅÂ(°¿øÅ×Å©³ëÆÄÅ©)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 11:00~11:30 µðÁöÅÐÇコ¿Í µ¥ÀÌÅÍÈ°¿ë Á¤»óÅÂ(À²ÃÌ)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 13:00~13:30 ¶óÀÌÇÁ·Î±× ºòµ¥ÀÌÅÍ Ç÷§Æû Ȳ»ó¿ø(¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 13:30~14:00 µðÁöÅÐÇコ ½Ã´ë Áø·áÁö¿ø Ç÷§Æû ±èÀÍ¿ë(¿¬¼¼´ëÇб³ ¿øÁÖÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 14:00~14:30 µðÁöÅÐÇコ¿Í ¸ÞŸ¹ö½º Â÷¿øö(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 14:30~15:00 ¸ÞµðÄà ƮÀ©°ú µðÁöÅÐÇコ ÀÌÁ¾±Ù(¹Ì¼ÒÁ¤º¸±â¼ú)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 15:00~15:30 ÀÇ·á 3D ¸ðµ¨¸µ ¹Ú»óÁØ(¸ÞµðÄþÆÀÌÇÇ)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 15:30~16:00 The Microbiome as Pharmabiotics ±ÇÈ£±Ù(¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 16:00~16:30 Systems Genetic Analysis of Atherosclerosis and Gut Microbiota in a Diversity Outbred F1 Mouse Population ±è¸í¼®(KIST°¸ª õ¿¬¹°¿¬±¸¼Ò)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 16:30~17:00 Diverse Microbiome Approaches to Unravel Different Biological Questions ½ÃÁö¿¬(KIST°¸ª õ¿¬¹°¿¬±¸¼Ò)
±³À°½Ã°£ 06¿ù 29ÀÏ 318È£ 17:00~17:30 Crosstalk Between Bacterial Lipid Immunogens and Human Immune System ¹è¹®Çü(°¡Ãµ´ëÇб³)
±³À°½Ã°£ 06¿ù 29ÀÏ 209È£ 13:30~14:15 ±âÈĺ¯È¿Í °Ç° ±è¹ÌÁö(°æ»ó±¹¸³´ëÇб³ ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 209È£ 14:15~15:00 ±âÈĺ¯È¿Í ¿øÃ漺 ±â»ýÃæ°¨¿°º´ ´ëÀÀ: Á¢±Ù ¹× Á¦¾îµµ±¸ ³ëÁÖȯ(Çѱ¹ÆĽºÅ𸣿¬±¸¼Ò)
±³À°½Ã°£ 06¿ù 29ÀÏ 209È£ 15:30~16:15 º´¿ø¼º ¸Å°³¸ð±âÀÇ ±âÈĺ¯È¿¡ µû¸¥ ºÐÆ÷ ÃÖ±¤½Ä(°æºÏ´ëÇб³ »ý¸í°úÇкÎ)
±³À°½Ã°£ 06¿ù 29ÀÏ 209È£ 16:15~17:00 ±¹³» ÂüÁøµå±â ¹× ÂüÁøµå±â ¸Å°³¼º º´¿øüÀÇ ºÐÆ÷¿Í ±âÈĺ¯È ½Å¼º½Ä(Àü³²´ëÇб³ ¼öÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 103È£ 14:00~14:25 A Precise Pathological Study Targeting Living Individuals ±è¿ëÁØ(°æÈñÀÇ´ë º´¸®Çб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 103È£ 14:25~14:50 Thoughts on Roles and Rresponsibilities as Bioinformatician in Pathology ¹ÚÀÎÈ£(¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 06¿ù 29ÀÏ 103È£ 14:50~15:15 Pathology, Biobank and My Studies ä¼öõ(¿ø±¤ÀÇ´ë º´¸®Çб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 103È£ 15:15~15:40 RNA Cancer Biology in Molecular Pathology ³²¼®¿ì(°¡Å縯ÀÇ´ë º´¸®Çб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 103È£ 15:40~16:05 A Retrospective of 10 Years as a Toxicologic Pathologist in the Pathology Department of a Major Hospital ¼Õ¿ìÂù(¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 29ÀÏ 103È£ 16:15~16:40 Role of Patholgists in Drug Development ÃÖÁØÁ¤(¿¬¼¼´ë ¾àÇаú)
±³À°½Ã°£ 06¿ù 29ÀÏ 103È£ 16:40~17:05 A Journey to a Physician-Informatician and Entrepreneur ¹Ú·¡¿õ(¾ÆÁÖÀÇ´ë ÀÇ·áÁ¤º¸Çб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 103È£ 17:05~17:30 Hospital Pathologists, Public Service Pathologist, and IT Pathologist ±è´ëö(Infinity)
±³À°½Ã°£ 06¿ù 29ÀÏ 323È£ 14:00~14:30 Identification and characterization of new neutrophil populations ¹è¿Ü½Ä(¼º±Õ°ü´ëÇб³ ÀÚ¿¬°úÇдëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 323È£ 14:30~15:00 The role of novel SiglecF+ neutrophils in fibrosis ±èÇý¿µ(¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 323È£ 15:00~15:30 Role of innate immune sensors and inflammation in viral infections ÀÌ»óÁØ(UNIST »ý¸í°úÇаú)
±³À°½Ã°£ 06¿ù 29ÀÏ 323È£ 16:00~16:30 Macrophage metabolism and inflammation programmed by MsrB1-regulated GAPDH oxidation ±èÁöÇü(°í·Á´ëÇб³ »ý¸í°úÇаú)
±³À°½Ã°£ 06¿ù 29ÀÏ 323È£ 16:30~17:00 Neutrophils fuel non-alcoholic fatty liver disease through lipid delivery È«Àå¿ø(°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 323È£ 17:00~17:30 Role of p38 MAPK in the Development of Neutrophil-driven Nonalcoholic Steatohepatitis Ȳ¼ºÈ¯(ºÎ»ê´ëÇб³ ¾àÇдëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 102È£ 13:30~13:55 In and out of mitosis by BubR1 acetylation/deacetylation ÀÌÇö¼÷(¼¿ï´ëÇб³ »ý¸í°úÇкÎ)
±³À°½Ã°£ 06¿ù 29ÀÏ 102È£ 13:55~14:20 Mitosis Selective Anti-Cancer Strategy Through Ubiquitination Control ÀÌâ¿ì(¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 102È£ 14:20~14:45 Identification of a novel HASPIN inhibitor and its synergism with the PLK1 inhibitor Â÷ÇõÁø(¼¿ï´ëÇб³ ¾àÇдëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 102È£ 14:45~15:10 DOT1L Methyltransferase as a Cell Cycle Regulator ±èÀÚÀº(°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 102È£ 15:30~15:55 Dysregulation of the centriole numbers in selected cancer cells À̰Ǽö(¼¿ï´ëÇб³ »ý¸í°úÇкÎ)
±³À°½Ã°£ 06¿ù 29ÀÏ 102È£ 15:55~16:20 Centrosome mediates mitotic catastrophe induced by DNA damage response Àå⿵(¼÷¸í¿©ÀÚ´ëÇб³ ¾àÇдëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 102È£ 16:20~16:45 The role of polo-like kinase 1 in hypomethylating treatment failure ±èÀ¯Áø(°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ)
±³À°½Ã°£ 06¿ù 29ÀÏ 104È£ 13:40~13:55 ¸ðµç ÀÇ»çµéÀÌ °®Ãß¾î¾ß ÇÒ ¿¹¹æÀÇÇÐ ±³À°À» À§ÇÏ¿©: ÀÇÇаú±³À° ¹ßÀüÀü·« ¿ÀÁÖȯ(¿¹¹æÀÇÇÐȸ ÀÇÇаú ±³À°À§¿øÀå)
±³À°½Ã°£ 06¿ù 29ÀÏ 104È£ 13:55~14:10 »çȸ¿Í °³ÀÎÀ» Á¾ÇÕÀûÀ¸·Î ÀÌÇØÇÏ´Â ÀÇ»ç ¾ç¼ºÀ» À§ÇØ ÇÊ¿äÇÑ ÀÇÇаú ¿¹¹æÀÇÇÐ ±³À° ÀÌ°ü(µ¿±¹ÀÇ´ë ¿¹¹æÀÇÇб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 104È£ 14:10~14:25 °³ÀÎÀ¸·Î ȯ¿øµÇÁö ¾Ê´Â °Ç°ÀÇ °áÁ¤¿äÀÎÀ¸·Î¼ÀÇ È¯°æ¿äÀÎÀ» È¿°úÀûÀ¸·Î ´Ù·ç´Â ÀÇ»ç ¾ç¼ºÀ» À§ÇÑ ÀÇÇаú ±³À° ÇϹ̳ª(´Ü±¹ÀÇ´ë ¿¹¹æÀÇÇб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 104È£ 14:25~14:40 Áö¿ª»çȸ°Ç°Çâ»óÀ» À§ÇÑ °³ÀÎÀû °Ç°°áÁ¤¿äÀÎ º¯È¸¦ À̲ø ¼ö ÀÖ´Â ¿ª·®À» °®Ãá ÀÇ»ç ¾ç¼ºÀ» À§ÇÑ ÀÇÇаú ±³À° °À±½Ä(°æ»óÀÇ´ë ¿¹¹æÀÇÇб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 104È£ 14:40~14:55 °¡Ä¡¿Í Áö¼Ó°¡´É¼ºÀ» ÁöÇâÇÏ´Â ±¹°¡¿Í Áö¿ª»çȸ ÀÇ·á½Ã½ºÅÛ °ü¸® ¿ª·®À» °®Ãá ÀÇ»ç ¾ç¼ºÀ» À§ÇÑ ÀÇÇаú ±³À° ¹ÚÀçÇö(¼º±Õ°üÀÇ´ë »çȸÀÇÇб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 104È£ 14:55~15:10 ¸ðµç Àǻ簡 °®Ãâ ¼ö ÀÖ´Â ¿¹¹æÀÇÇÐ Áö½Ä°ú ¼Ò¾ç ±³À°À» À§ÇÑ »õ·Î¿î ¿¹¹æÀÇÇÐ ±³°ú¼ ÆíÂù ±ÇÈ£Àå(¿¹¹æÀÇÇÐ ±³°ú¼ ÆíÁýÀ§¿øÀå)
±³À°½Ã°£ 06¿ù 29ÀÏ 104È£ 15:10~15:25 ±³À°ÀÇ º¯È °üÁ¡¿¡¼ º» ÀÇÇаú ±³À°ÀÇ ¹Ì·¡ ¸ð¹üÀ¸·Î¼ÀÇ ¿¹¹æÀÇÇÐ ±³À°ÀÌ µÇ·Á¸é À̽ÂÈñ(¼¿ïÀÇ´ë ÀÇÇб³À°Çб³½Ç)
±³À°½Ã°£ 06¿ù 29ÀÏ 104È£ 15:25~15:40 ÀÇÇб³À°ÇÐ‧¿¹¹æÀÇÇÐ µ¿½ÃÀû °í·Á¸¦ ÅëÇØ º» ÀÇÇаú ±³À° °úÁ¤¿¡¼ ¿¹¹æÀÇÇÐÀÇ ¹ßÀüÀû ¿ªÇÒ Ã¤À¯¹Ì(´Ü±¹ÀÇ´ë ÀÇÇб³À°Çб³½Ç)
Åä·Ð 06¿ù 29ÀÏ 104È£ 15:40~16:00 Á¾ÇÕ Åä·Ð ()
±³À°½Ã°£ 06¿ù 29ÀÏ 105È£ 14:10~14:40 An Integrative Approach to Cancer Precision Medicine Á¶¼º¿±(¼¿ï´ëÇб³)
±³À°½Ã°£ 06¿ù 29ÀÏ 105È£ 14:40~15:10 AD Drug Candidates Targeting Both Amyloid Abnormalities and Neuroinflammation ¾ç½ÂÈÆ(µ¿±¹´ëÇб³)
±³À°½Ã°£ 06¿ù 29ÀÏ 105È£ 15:10~15:40 TLR5: A Promising Therapeutic Target for the Treatment of Various Diseases Á¶°æ¾Æ(Àü³²´ëÇб³)
±³À°½Ã°£ 06¿ù 29ÀÏ 105È£ 16:00~16:30 Deciphering the Novel Intrinsic System in T cells Ȳ¼ö¼®(¿¬¼¼´ëÇб³)
±³À°½Ã°£ 06¿ù 29ÀÏ 105È£ 16:30~17:00 Trend of Therapeutic Intervention Using Stem Cells in Spinal cord Injury À±Å¿µ(°æÈñ´ëÇб³)